GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.
A user seeks advice on mixing RU58841 serum using European ingredients, specifically struggling to find propylene glycol. They are looking for alternatives to American products commonly recommended in guides.
Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
Switching from 1mg finasteride to dutasteride, with users recommending starting at 0.5mg daily. Some users prefer capsules, while others use tablets, citing effectiveness and regulatory approval in Asia.
Topical estrogen or estradiol for hair loss is being discussed for its effectiveness compared to finasteride. Users are sharing their experiences and opinions on its potential benefits.
A user is experiencing side effects like less hard erections and sensitive nipples while on finasteride, with bloodwork showing high prolactin levels. They are seeking suggestions to address the prolactin issue.
Some users have experienced good hair regrowth with estradiol, cyproterone acetate, spironolactone, and bicalutamide, but these treatments may cause feminization and other side effects. It's advised to consult a doctor before using these treatments, as they can lower testosterone and have significant risks.
The post discusses using Mucuna pruriens, essential oils, and dermarolling for hair loss treatment. The user also mentions pausing testosterone-boosting herbs due to side effects like acne and hair loss.
The user is treating male pattern baldness with oral minoxidil, ketoconazole, derma rolling, rosemary oil, and topical minoxidil, and is considering adding finasteride. They are debating between three finasteride dosing strategies: 1mg daily, 1.25mg every other day, or 1.25mg five days a week, focusing on efficacy, safety, and cost.
The conversation discusses a last-resort hair loss treatment combining topical finasteride, minoxidil, melatonin, and progesterone, with claims that topical finasteride can inhibit up to 52% of scalp DHT. One reply clarifies that progesterone is not an anti-androgen but has anti-androgenic properties because it competes with androgens for receptors.
Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.
The user experienced side effects from using 1% finasteride and 2% minoxidil, including dermatitis, erectile dysfunction, and heart palpitations. They switched to using 2000mg pumpkin seed oil, saw palmetto capsules, and applying pumpkin seed oil and rosemary oil twice a week, seeking feedback on results.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The conversation discusses using gartanin from mangosteen mixed with castor oil to degrade the androgen receptor for hair loss treatment. Alternatives like setipiprant, minoxidil, and dermastamping are also mentioned, with concerns about cost and potential side effects.
Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
The post discusses a user's successful hair regrowth using finasteride, dutasteride, topical minoxidil, and estrogen over nine months. The user, who is male-to-female (mtf), reports significant regrowth and no side effects beyond typical hormone replacement therapy effects.